SCHEMBL23753783

SCHEMBL23753783

CC(=O)c1cc(F)ccc1-c1cnn(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 2/20 0.48
▸ BRD4 O60885 1/20 0.48
▸ MAP4K4 O95819 1/20 0.44
▸ MET P08581 3/20 0.44
▸ ABL1 P00519 2/20 0.43
▸ RIPK1 Q13546 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ ALOX5AP P20292 1/20 0.42
▸ FEN1 P39748 1/20 0.42
▸ CREBBP Q92793 1/20 0.42
▸ GRM2 Q14416 1/20 0.41
▸ HCRTR1 O43613 1/20 0.41
▸ BTK Q06187 1/20 0.41
▸ USP30 Q70CQ3 1/20 0.41
▸ SMARCA2 P51531 1/20 0.41
▸ SMARCA4 P51532 1/20 0.41
▸ IKBKE Q14164 1/20 0.41
▸ TBK1 Q9UHD2 1/20 0.41
▸ CLK2 P49760 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31048540 0.79 PDK2 (0.55) PDK2BRD4GRM2BTKSMARCA2
SCHEMBL23753928 0.77 PDE9A (0.47) BRD4MAP4K4METRIPK1FGFR1
SCHEMBL20186915 0.77 SLC22A12 (0.52) PDK2BRD4MAP4K4GRM2IKBKE
SCHEMBL18124158 0.75 TGFBR1 (0.48) BRD4METABL1ALOX5APFEN1
SCHEMBL13735623 0.74 ABL1 (0.57) BRD4MAP4K4ABL1FGFR1CREBBP
SCHEMBL10094634 0.74 LRRK2 (0.48) BRD4ABL1ALOX5APFEN1BTK
SCHEMBL26505596 0.74 GPR55 (0.46) PDK2BRD4MAP4K4METALOX5AP
SCHEMBL28852787 0.74 ALK (0.43) BRD4FGFR1ALOX5APFEN1LRRK2
SCHEMBL28126166 0.73 HTT (0.51) —
SCHEMBL31677710 0.73 LRRK2 (0.50) BRD4MAP4K4METALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115135648-B Dihydronaphthyridones, preparation method and medical application thereof 劲方医药科技(上海)有限公司 2024-02-09 — — CN disclosed
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-05-04 — — US disclosed
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-05-04 — — US disclosed
EP-4105216-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2022-12-21 — — EP disclosed
CN-115135648-A Dihydronaphthyridinone compounds, preparation method and medical application thereof 劲方医药科技(上海)有限公司 2022-09-30 — — CN disclosed
WO-2021160109-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 劲方医药科技(上海)有限公司 2021-08-19 — — WO disclosed
WO-2021160109-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 劲方医药科技(上海)有限公司 2021-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF RIPK1, RIPK4, RIPK3 PDK2 300/4885BRD4 3261/4885MAP4K4 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback